At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 21 enrolled
Drug / intervention
Imatinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Non-Randomized, Multiple Dose, Three Treatment Period, Open-Label, Single Sequence, Single Group Study to Evaluate the Pharmacokinetic Effect of Two Doses of QTI571 (Imatinib) on the Co-administered Drugs Sildenafil and Bosentan in Pulmonary Arterial Hypertension (PAH) Patients
In Brief
A Phase 3 clinical trial evaluating Imatinib, Sildenafil, and 1 other intervention for Pulmonary Arterial Hypertension. Completed, enrolled 21 participants across 11 sites in 7 countries.
Detailed Summary
The purpose of this study was to investigate the effects of QTI571 (imatinib) on pharmacokinetics of bosentan and sildenafil at steady state when co-administered to participants with pulmonary arterial hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Arterial Hypertension
CountriesAustralia, Belgium, Germany, Italy, Lithuania, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2011
First PostedJul 2011
Primary CompletionOct 2012
TodayJul 2026
First PostedJul 12, 2011
Enrollment StartApr 20, 2011
Primary CompletionOct 25, 2012
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 15.0 years ago
Interventions
Imatinibdrug
Film coated tablets, oral administration
Sildenafildrug
Oral Administration
Bosentandrug
Oral Administration